EGFR and non-small cell lung carcinoma: Erlotinib, a kind of OSI Pharmaceuticals, has been reported as an inhibitor of the tyrosine kinase activity of EGFR,53, 54 which is efficiently used to prolong the lifetime of the previously treated patients with NSCLC.55, 56 In the GDSC dataset, there are 286 out of 652 cell lines with known response values to erlotinib.